| Melissa Warren, MD | |
|
3601 The Vanderbilt Clinic, Nashville, TN 37232-3504 | |
| (615) 936-2000 | |
| Not Available |
| Full Name | Melissa Warren |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | 3601 The Vanderbilt Clinic, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558652388 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 55001 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vanderbilt University Medical Center | 5092023416 | 2711 |
News Archive
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based on their symptoms.
Today, in an effort to acknowledge the vital services of rural healthcare practitioners across Colorado, State Representative Tom Massey (R-CO), will introduce a House Joint Resolution to recognize "Rural Health Day."
› Verified 5 days ago
| Entity Name | Vanderbilt University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104202761 PECOS PAC ID: 5092023416 Enrollment ID: O20151006000369 |
News Archive
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based on their symptoms.
Today, in an effort to acknowledge the vital services of rural healthcare practitioners across Colorado, State Representative Tom Massey (R-CO), will introduce a House Joint Resolution to recognize "Rural Health Day."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Warren, MD 3841 Green Hills Village Dr Ste 200, Nashville, TN 37215-2691 Ph: () - | Melissa Warren, MD 3601 The Vanderbilt Clinic, Nashville, TN 37232-3504 Ph: (615) 936-2000 |
News Archive
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based on their symptoms.
Today, in an effort to acknowledge the vital services of rural healthcare practitioners across Colorado, State Representative Tom Massey (R-CO), will introduce a House Joint Resolution to recognize "Rural Health Day."
› Verified 5 days ago
Megan Desai, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4220 Harding Pike, Nashville, TN 37205 Phone: 615-222-6726 Fax: 615-222-3702 | |
Harrison Klause, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
John N Bowers, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike Ste 500, Nashville, TN 37205 Phone: 629-255-2493 Fax: 629-255-4266 | |
Dr. Evan Zehr, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1161 21st Ave S, Nashville, TN 37232 Phone: 615-322-6943 | |
Spurthi N Bhatt, MD MPH Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Mr. Robert M Johnson, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2410 Patterson St, Suite 106, Nashville, TN 37203 Phone: 615-340-4611 Fax: 615-340-4658 | |
Mr. John E Anderson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 400, Nashville, TN 37203 Phone: 615-342-5900 Fax: 615-342-5912 |